Introduction
Diabetes mellitus (DM) is the most important risk factor for coronary artery disease (CAD) and stroke [1] . Patients with DM have higher risk of CAD than non-diabetic patients [2] . More than 80 % of all lethal outcomes in patients with DM are caused by atherosclerosis [1] . These patients more frequently have severe CAD and mortality from stroke than non-diabetic patients [1] . Having in mind their poor prognosis, in these patients the choice of the best CAD treatment (lifestyle correction, pharmacological, revascularization, surgery) is of crucial importance [3] . Patients with severe CAD and DM often have multivessel disease and they are more frequently candidates for Coronary Artery Bypass Graft (CABG) surgery than non-diabetics patients [4, 5] . On the other hand, revascularization with the use invasive percutaneous coronary intervention (PCI) is a more recent method in medicine due to its effectiveness in removing the most severe outcomes of coronary ischemia [6] . In order to closely monitor the treatment effects in patients with CAD and DM, and to improve medical decision-making in the choice between different alternatives and precise predictions related to the most important therapeutic outcome such as Major Adverse Cardiac Events (MACE), there was a need to develop unique angiographic and/or clinical instruments for CAD complexity measurement.
The SYNTAX score is an angiographic grading tool for determining the complexity of CAD undergoing patient's revascularization in combination with angiographic classifications aiming to grade the coronary anatomy with respect to the number of lesions, their location and functional impact of angiographically obstructive lesions [7] [8] [9] [10] [11] . In SYNTAX trial after various longer follow ups, different -cut points‖ for the SYNTAX score are defined, which determine the level of risk for the primary outcome of CAD treatment. Thus, it is defined that patients with SYNTAX ≤22 have less complex CAD and better treatment outcomes [12] [13] [14] . SYNTAX score has predictive value in different clinical settings including acute coronary syndrome (ACS) [7, 11, [15] [16] [17] [18] [19] [20] [21] .
Modification of original ACEF score [22] was recently presented and used age, serum creatinine and ejection fraction of the left ventricle for adverse cardiovascular events prognosis in patients with DM and ACS resulted in modified ACEF score, which uses clearance creatinine instead of serum creatinine since it provides a better assessment of renal function and improves predictive value in cardio vascular risk assessment, especially with regard to the prediction of the development of MACE [23, 24] .
However, there are no reports of the development of a predictive tool, which would combine the assessment of anatomical, clinical and metabolic risk factors for MACE in patients with ACS and DM. The aim of this study was assessment of the adequacy and criterion validity of a risk index which combines the SYNTAX score, the modified ACEF score and the metabolic risk factors for one-year MACE in patients with ACS and DM, who underwent PCI.
Methods

Study Design
The study was designed as a prospective, cross sections study in patients with ACS and DM, who underwent PCI and who were monitored by one-year MACE and was conducted in the period 2012-2014 at the Department of Cardiology and Invasive Cardiology, General Hospital Valjevo, Valjevo, Serbia. The study was approved by the local Ethics Committee and all the patients signed informed consent form.
Patients
The study population included patients who underwent PCI, men and women, older than 18, with ACS and DM. Patients have diagnosis of DM for at least one year according to current guidelines. ACS was defined as: (1) acute myocardial infarction with ST elevation (STEMI) in the patient with characteristic symptoms of myocardial ischemia lasting for more than 20 min in association with persistent electrocardiographic ST elevation (STE) of more than 1 mm (0.1 mV) in two or more contiguous leads, or new, or presumed new left bundle branch block and subsequent release of biomarkers of myocardial necrosis; (2) acute myocardial infarction without electrocardiographic ST elevation (NSTEMI) in the patient with characteristic symptoms of acute chest pain lasting for more than 20 min accompanied by ST depression of more than 1 mm (0.1 mV) and T wave inversion in two or more contiguous leads, with positive biomarkers of myocardial necrosis and (3) unstable angina pectoris (UAP) in the patient with characteristic symptoms of acute chest pain lasting for more than 20 min accompanied by electrocardiographic ST depression of more than 1 mm (0.1 mV) and T wave inversion in two or more contiguous leads, with negative biomarkers of myocardial necrosis. Patients with previous CABG or PCI on coronary arteries and patients with cardiogenic shock were not included in the study.
Procedures
According to the primary PCI (pPCI) protocol, only culprit lesion was treated during procedure. pPCI was performed in STEMI patients up to 48 hours from the onset of characteristic symptoms of myocardial ischemia. The decision whether to treat non-culprit lesions during pPCI in STEMI patients with multivessel disease was based on angiographic severity of the lesion (diameter stenosis of 50 % or more). The invasive PCI procedure (stenting) in NSTEMI patients was based on angiographic severity of the lesion (diameter stenosis of 50 % or more), exclusively for up to 72 hours from the onset of myocardial ischemia symptoms. The invasive PCI procedure in UAP patients was performed electively based on angiographic severity of the lesion (diameter stenosis of 50 % or more).
Outcomes
MACE as a primary end point was defined as all deaths, nonfatal myocardial infarction, nonfatal cerebrovascular insult (CVI) and repeated PCI or need for CABG that were assessed within oneyear observation. After a one-year follow-up patients were divided into two groups: patients with MACE and patients without MACE.
Variablesrisk factors
Following risk factors were recorded for all the patients: age, gender, categories of ACS, categories of DM (Type 1 or Type 2), therapy of DM (with insulin or without insulin), Glycosylated Hemoglobin (HbA1c) in %, HbA1c ≥8 % (unregulated DM), total cholesterol (mmol/L), total cholesterol ≥4.5 mmol/L (high level in diabetes), triglycerides (mmol/L), triglycerides ≥2.3 mmol/L (high or very high level), SYNTAX score, SYNTAX score >21 and modified ACEF score.
Estimated Glomerular Filtration rate (eGFR) was calculated using Cockroft-Gault formula. Renal insufficiency was defined as eGFR <60 ml/min. Left ventricular ejection fraction (LVEF) was assessed by echocardiographic examination in the first 24 h after pPCI, using Simpson's biplane method. Severe LVEF was defined as LVEF <40 %.
Modified ACEF score is calculated using the formula: years/EF +1 point for every 10 ml/min reduction in clearance creatinine lower than 60 ml/min to 1.73 m2 (to maximum 6 points). Therefore, clearance creatinine between 50-59 ml/min to 1.73 m2, 49-49 ml/min to 1.73 m2, 30-39 ml/min to 1.73 m2 will get 1, 2 or 3 points. The criterion value of modified ACEF for MACE detection was evaluated after completion of the study and was also used as a predictor variable of the above outcomes.
SYNTAX score was calculated in the manner described by Brkovic et al, 2013. [7] . All angiographic variables pertinent to calculation were computed by two interventional cardiologists who were blind to procedural data and clinical outcome. In case of disagreement, the opinion of the third observer was obtained, and the final decision was made by consensus.
Statistical methods
Continuous numerical data sets were described by the mean and standard deviation. The attributive or ordinal variables were described by the frequency of outcomes and percentages. Univariable analysis was performed using Pearson chi-square test or Fisher's exact test for categorical variables and Student t test for continuous variables.
Binary logistic regression method with stepwise variable selection was used for multivariate analysis of MACE risk factors. All variables that had a p <0.1 on univariable analyses were considered for inclusion in the final model.
The evaluation of the validity of the logistic regression model implied an assessment of its goodness-of-fit measure and its accuracy. Goodness-of-fit model was made by estimating the Nagelkerke R Square. The accuracy of the logistic regression model was assessed using discrimination and adequacy. Discrimination measures were conducted to prove how adequately a model can distinguish patients with MACE from patients without MACE. The analysis of the adequacy of logistic models and the estimate of the retention of variables or their interactions was made using the Hosmer-Lemeshow method. Discrimination validity of the predicted probabilities obtained by logistic regression model and/or the newly constructed Major Adverse Cardiac Events Risk Index (MACERI) in distinguish MACE positive vs MACE negative patients was estimated by Receiver Operating Characteristic (ROC) procedure. -Cut point‖ value, sensitivity, specificity, positive predictive value and negative predictive value were obtained by applying maximum Youden index. The testing of the significance of the difference between the areas under the curve (AUC) or c statistic of the newly constructed MACERI in relation to the AUCs of other scales was performed by the DeLong method.
The accepted level of significance was p = 0.05. Statistical programs IBM SPSS Statistics 20 (NY) was used for the data processing and MedCalc 12.5.0 (Belgium).
Development of MACERI
Once the model was developed using the regression equation, it was used to develop MACERI. We used the method described in the Framingham study [25] for conversion of the parameter of estimated regression model into an index. The number of points assigned to each variable equaled its regression coefficient divided by 0.5, followed by rounding to the nearest whole number. The points for each risk factor were then summed to obtain the total number of points (score) for a patient. Formula for back-transforming from logistic regression estimated score to probability was as follows:
where natural logarithm is presented with "e".
Results
The study included 136 consecutive patients with ACS and DM who were all subjected to PSI, of which 55 patients developed at least one MACE in a one-year follow-up period. 28 Compared to the non-MACE patients' group, patients with MACE were older and had higher values for SYNTAX score, higher values for modified ACEF scores, as well as all higher values for variables used to calculate modified ACEF (Tab. 1). Patients with MACE also had higher average values for HbA1c (%) than non-MACE patients. Among the groups of patients there was no difference in the total cholesterol level (mmol/L) and level of triglycerides (mmol/L) -Tab 1.
Compared to non-MACE patients, patients with MACE had more frequent unregulated diabetes (HbA1c >8 %) and cardiac insufficiency (LVEF = 40 %), more frequent SYNTAX score >21 and modified ACEF score >1.38 and also loss frequent pPCI and loss frequent stenting in UAP patients and NSTEMI patients (Tab. 2). By using univariable testing, in all remaining variables no significant difference was found in the distribution of outcome rates between patients' groups.
By applying multivariable regression analysis, we identified four independent risk factors and one interaction between two risk factors for MACE and after which we made the allocation of appropriate points to form the MACERI (Tab. 4): (1) modified ACEF score >1.38; + 4 point; (2) UAP; + 2 points; (3) SYNTAX score >21; + 3 points; (4) HbA1c ≥8 %; + 2 points and (5) the interaction between insulin terapy and triglycerides ≥2.3 mmol/L; + 5 points. The above model showed moderate level of goodness-of-fit measure (Nagelkerke R Square = 0.537) and very good discriminating characteristics (Tab. 4) and adequacy (Hosmer-Lemeshow test Chi square = 8.271; p = 0.219). MACERI >7 was the criteria for detection of very high MACE risk, that corresponded with estimated probability (or individual patient risk) for MACERI >0.44 (Tab. 3 and Tab. 5). Based on 95 % confidence interval for MACERI -cut point‖ in MACE detection (Tab. 3), we formed three levels of risk for the patient, as a low risk, increased risk and very high risk (Tab. 5). Average MACERI in the non-MACE patients' group was 4.65 ± 3.14, while in the group of patients with MACE was 9.62 ± 2.85.
By DeLong method, we found the difference in the AUC for MACERI versus the AUC for the SYNTAX score (Difference between areas = 0.0814; 95% Confidence interval from 0.00748 to 0.155; z = 2.158; p = 0.031). Also, we found the difference in the AUC for MACERI versus the AUC for the modified ACEF score (Difference between areas = 0.135; 95% Confidence interval from 0.0522 to 0.218; z = 3.195; p = 0.0014). However, there was no difference in AUC for SYNTAX score compared to the AUC for modified ACEF score (Difference between areas = 0.0536; 95% Confidence interval from -0.0580 to 0.165; z = 0.942; p = 0.346).
Discussion
In our study, we first performed an assessment of the association of metabolic, anatomicangiographic and clinical risk factors for the development of one-year MACE in patients with ACS and DM, who underwent PCI. We found that there was a combined impact of these risk factors in the study population and formed MACERI composed of the following significant risk factors: HbA1c > 8%, triglicerydes >2.3 mmol/L in patients with insulin therapy, UAP diagnosis, SYNTAX score >21 and modified ACEF score >1.38.
In terms of HbA1c, our results support the recommendations of the American Diabetes Association (ADA) that in patients with DM and advanced microvascular (including ACS) and macrovascular complications, the target HbA1c values should be less restrictive (HbA1c < 8%) [26] . As the same ADA criteria were set for patients with frequent development of hypoglycaemia, ADA wants to prevent further compromise of multivessel CAD that would result from potential development of hypoglycaemia in patients with poor glucoregulation. Bearing in mind the -cut point‖ for MACERI estimated in this study, we note that strict adherence to ADA recommendations potentially can avoid one-year MACE in patients with ACS and DM, even in cases where they additionally have SYNTAX score >22 or modified ACEF score >1.38.
In our study, a very high risk of one-year MACE in patients with insulin therapy and triglycerides ≥2.3 mmol/L was assessed. Since this risk is completely independent of the risk arising from HbA1c ≥8 %, this is the result of suboptimal insulin patients' therapy and their lifestyle. Therefore, we consider that correction of patient's lifestyle would be unsuccessful, and that they require intensive treatment with statins and fibrates at the same time in accordance with the recommendations of the European Association for Cardiovascular Prevention and Rehabilitation [27] . However, if these patients also have HbA1c ≥8 %, there is a need to optimize their insulin therapy with the permanent measurement of glycemic profiles. This last point is highlighted taking into account -cut point‖ and scoring system for MACERI (Tab.3-Tab. 5) that indicates that patients with insulin therapy and triglycerides ≥2.3 mmol/L associated with HbA1c ≥8 % have a very high risk of develop a one-year MACE, even when they have SYNTAX score ≤22 and modified ACEF score ≤1.38.
We evaluated that patients with UAP compared to the reference group of patients with STEMI have had an increased risk for one-year MACE (Tab. 5). The reason for this is seen in the reduced rate of invasive PCI in these patients compared to patients with STEMI (28.8 % versus 57 %) -Tab. 2. Therefore, in the future it is important to consider more precise criteria for the implementation of invasive PCI in patients with UAP and DM, as our results suggest that more frequent stent placement in these patients could be beneficial in terms of reducing the risk of one-year MACE after PCI. It is also suggested that this risk in patients with UAP in relation to the reference category of patients with STEMI can be indirectly associated with a rarely implemented invasive PCI. Namely, all patients who underwent the invasive PCI certainly have had a permanently monitored dual aggregation therapy in the observed one-year follow-up.
In this study it was shown that there was no difference in AUC for SYNTAX score versus AUC for modified ACEF in the detection of risk of a one-year MACE. A similar result was demonstrated in Pivato et al, 2018, who analyzed a mixed population with/without DM and ACS, but also a one-month follow-up after PCI [24] . In any case, we showed that the MACERI had significantly better ROC characteristics, both in relation to the modified ACEF score and in relation to SYNTAX score.
In the review Yadav et al, 2013, they emphasize the necessity to precisely determine the -cut point‖ for the SYNTAX score for MACE detection in patients with DM and ACS with longer follow-up period after PCI [28] . We estimated that the -cut point‖ for the SYNTAX score in the one-year MACE is 22 (18.8 to 24.5) . In the reports of other authors, the values for the SYNTAX score defined by the mentioned interval are similar, both in the prediction of MACE [17, 29] , and in the assessment of associated risk factors in severe CAD forms [30, 31] .
Study limitation
The limitations of this study are single center design, relatively small sample size, and noninclusion in the evaluation of variables such as stent number, stent types, left main disease, culprit-only PCI and others. The performance of our studies, including the formation of attitudes of a variety of methods during PCI, and the definition of repeat revascularization as adverse events, corresponds to the time when said attitudes are still applicable and have been the subject of controversy [32] . However, such attitudes have now been overcome. As we did a crosssectional study of risk factors for the development of MACE in the population of patients treated with PCI at that time, then we could not ignore this fact by simply avoiding repeat revascularization within MACE. We emphasize that our study is not an intervention study, hence there is no design, sample size, power and methodological basis for a clear assessment between the various procedures in the course of the PCI.
The major limitation of SYNTAX score is that estimates only anatomical complexity and distribution of coronary artery disease. SYNTAX II score combines clinical and anatomical risk estimation, but needs still to be validated in prospective cohorts.
Conclusion
Major Adverse Cardiac Events Risk Index is highly adequate in predicting the most important one-year adverse events of patients with diabetes mellitus and acute coronary syndrome who underwent percutaneous coronary intervention. This index combines the risks that arise from metabolic, angiographic and clinical variables, and as such is more accurate in the prediction of the mentioned events compared to the scale of which it is composed. AUCarea under the curve; SEstandard error; CIconfidence interval; Znormal distribution zed value; SNsensitivity; SPspecificity; PPVpositive predictive value; NPVnegative predictive value; MACERI -Major Adverse Cardiac Events Risk Index. 
